PMID- 16209208
OWN - NLM
STAT- MEDLINE
DCOM- 20070424
LR  - 20131121
IS  - 1009-3591 (Print)
IS  - 1009-3591 (Linking)
VI  - 11
IP  - 9
DP  - 2005 Sep
TI  - [Clinical study of Eviprostat for the treatment of benign prostatic hyperplasia].
PG  - 674-6
AB  - OBJECTIVE: To study the efficacy and safety of Eviprostat for the treatment of 
      benign prostatic hyperplasia (BPH). METHODS: An open, multicentral clinical trial 
      was conducted in 100 patients with BPH. Patients received a 12-week oral 
      administration of Eviprostat 2 tablets per-time, 3 times a day. The main indexes 
      of efficacy include international prostatic symptom score (IPSS), maximum urinary 
      flow rate (Qmax), residual urine ( Ru) and prostatic volume (V). The additional 
      indexes are quality of life score (QOL) and average urinary flow rate (Qave). 
      RESULTS: After a 12-week therapy, IPSS, QOL score, Qmax and Qave were 
      significantly improved. IPSS was averagely decreased by 5.67 (P < 0.001); QOL 
      score was averagely decreased by 1.44 (P < 0.001); Qmax was averagely increased 
      by 1.70 ml/s (P <0.001); Qave was averagely increased by 1.15 ml/s (P < 0.001); 
      Ru was averagely decreased by 5.07 ml (P = 0.046) , PSA level was averagely 
      decreased by 0.129 microg/L (P < 0.017). The clinical adverse event rate was 1%. 
      CONCLUSION: Eviprostat is a kind of safe, effective and preferable drug for 
      treating BPH. It can improve the subjective symptoms and objective measures of 
      the patients.
FAU - Song, Yi
AU  - Song Y
AD  - Institute of Urology, the First Hospital of Peking University, Beijing 100034, 
      China.
FAU - Li, Ning-chen
AU  - Li NC
FAU - Wang, Xiao-feng
AU  - Wang XF
FAU - Ma, Lu-lin
AU  - Ma LL
FAU - Wan, Ben
AU  - Wan B
FAU - Hong, Bao-fa
AU  - Hong BF
FAU - Na, Yan-qun
AU  - Na YQ
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
PL  - China
TA  - Zhonghua Nan Ke Xue
JT  - Zhonghua nan ke xue = National journal of andrology
JID - 101093592
RN  - 0 (Drug Combinations)
RN  - 0 (Plant Extracts)
RN  - 24YL531VOH (Ethamsylate)
RN  - 59738-67-9 (eviprostat)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Drug Combinations
MH  - Ethamsylate/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Plant Extracts/adverse effects/*therapeutic use
MH  - Prostatic Hyperplasia/*drug therapy
MH  - Quality of Life
MH  - Treatment Outcome
MH  - Urodynamics
EDAT- 2005/10/08 09:00
MHDA- 2007/04/25 09:00
CRDT- 2005/10/08 09:00
PHST- 2005/10/08 09:00 [pubmed]
PHST- 2007/04/25 09:00 [medline]
PHST- 2005/10/08 09:00 [entrez]
PST - ppublish
SO  - Zhonghua Nan Ke Xue. 2005 Sep;11(9):674-6.